Publicaciones en colaboración con investigadores/as de Generalitat de Catalunya (13)

2022

  1. Impact of COVID-19 Lockdown on the Nasopharyngeal Microbiota of Children and Adults Self-Confined at Home

    Viruses, Vol. 14, Núm. 7

2021

  1. Serotypes and Clonal Composition of Streptococcus pneumoniae Isolates Causing IPD in Children and Adults in Catalonia before 2013 to 2015 and after 2017 to 2019 Systematic Introduction of PCV13

    Microbiology Spectrum, Vol. 9, Núm. 3

  2. The positive rhinovirus/enterovirus detection and sars-cov-2 persistence beyond the acute infection phase: An intra-household surveillance study

    Viruses, Vol. 13, Núm. 8

2020

  1. Epidemiological, clinical, and microbiological characteristics of serotype-3 streptoccocus pneumoniae infection after a partial introduction of the 13-valent pneumococcal conjugate vaccine: A prospective observational study

    Journal of Pediatric Infectious Diseases, Vol. 15, Núm. 4, pp. 169-175

  2. Erratum for Hernández et al., "Invasive Pneumococcal Disease and Influenza Activity in a Pediatric Population: Impact of PCV13 Vaccination in Epidemic and Nonepidemic Influenza Periods"

    Journal of clinical microbiology

  3. Failures of 13-valent conjugated pneumococcal vaccine in age-appropriately vaccinated children 2-59 months of age, Spain

    Emerging Infectious Diseases, Vol. 26, Núm. 6, pp. 1147-1155

  4. Pneumococcal serotypes in children, clinical presentation and antimicrobial susceptibility in the PCV13 era

    Epidemiology and Infection

  5. Serotype and clonal distribution dynamics of invasive pneumococcal strains after PCV13 introduction (2011-2016): Surveillance data from 23 sites in Catalonia, Spain

    PLoS ONE, Vol. 15, Núm. 2

2019

  1. Complicated pneumococcal pneumonia with pleural effusion or empyema in the 13-valent pneumococcal conjugate vaccine era

    Pediatric Pulmonology, Vol. 54, Núm. 5, pp. 517-524

  2. Invasive pneumococcal disease and influenza activity in a pediatric population: Impact of PCV13 vaccination in pandemic and nonpandemic influenza periods

    Journal of Clinical Microbiology, Vol. 57, Núm. 8

2017

  1. Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study

    PLoS ONE, Vol. 12, Núm. 8

2012

  1. Clinical Presentation of invasive pneumococcal disease in Spain in the era of heptavalent conjugate vaccine

    Pediatric Infectious Disease Journal, Vol. 31, Núm. 2, pp. 124-128

  2. Serotype 3 is a common serotype causing invasive pneumococcal disease in children less than 5 years old, as identified by real-time PCR

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 31, Núm. 7, pp. 1487-1495